The US Food and Drug Administration has asked for public views on how it should weigh the benefits and risks of medical robots that act on their own, or that a doctor controls from another room, hospital or country. Its discussion paper, published on 6 November, is not a rule or draft guidance and sets no policy.
The FDA says that as of July 2026, “no remotely teleoperated or fully autonomous robotic device systems have been granted marketing authorization in the United States”, although robots with some autonomous features have been sold for years.
The paper lists possible gains: steadier, repeatable work in long operations, less strain on surgeons, and faster access to specialists for time-critical cases such as stroke and heart attack. It also lists risks: delays or dropped connections, a remote surgeon losing touch and sound, cyber attacks on commands or images, AI behaving unpredictably outside its training data, and staff either trusting the machine too much or overriding it when they should not.
Why it matters: remote surgery trials are moving quickly, including a US prostate operation from 35 miles away in October. How the FDA frames these risks will shape what makers must prove before such systems reach hospitals. Feedback is open until 5 January 2027 (docket FDA-2026-N-13135).
Related: Teleoperation (glossary) and How robots learn.
Primary source: FDA discussion paper